4Q 2018 Results and preliminary annual report | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
post-template-default,single,single-post,postid-18505,single-format-standard,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.7,vc_responsive

4Q 2018 Results and preliminary annual report

4Q 2018 Results and preliminary annual report

Moss, 28 February 2019

Gentian Diagnostics AS announces its results for the 4th quarter and 2018 preliminary annual results. The highlights include:

  • Record sales revenues of MNOK 11.1 for the quarter
  • 42 % growth in underlying sales revenue compared to 4Q17, 43 % year to date
  • All time high sales results achieved with fCAL® turbo


Please find the report here: GDAS 2018 4Q Interim report[2594] or on Oslo Børs NewsWeb.

For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525